2009
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E. When to start antiretroviral therapy in resource-limited settings. Annals Of Internal Medicine 2009, 151: 157-66. PMID: 19620143, PMCID: PMC3092478, DOI: 10.7326/0003-4819-151-3-200908040-00138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAnti-Infective AgentsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisDecision TreesDisease ProgressionDrug Administration ScheduleHealth Care CostsHIV InfectionsHumansLife ExpectancySensitivity and SpecificitySouth AfricaTrimethoprim, Sulfamethoxazole Drug CombinationConceptsAntiretroviral therapyCD4 countLong-term survivalCells/LART initiationCells/L.ART initiation strategiesIncremental cost-effectiveness ratioSevere opportunistic diseaseDoris Duke Charitable FoundationLife expectancyCD4 count thresholdHIV treatment decisionsCost-effectiveness ratioInternational clinical trialsBase-case analysisResource-limited settingsYears of lifeCost-effectiveness analysisPerson's life expectancyObservational cohortCD4 thresholdHIV diseaseTreatment guidelinesEarly therapy
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence
1993
The epidemiological and economic consequences of AIDS clinical trials.
Paltiel AD, Kaplan EH. The epidemiological and economic consequences of AIDS clinical trials. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1993, 6: 179-90. PMID: 8433283.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeClinical Trials as TopicCost-Benefit AnalysisDecision TreesHumansMalePolicy MakingConceptsClinical trials